trans-repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11435-11447

  Hughes, David J ^a,b   Dickerson, Carol A ^a   Shaner, Marie S ^a   Sample, Clare E ^a   Sample, Jeffery T ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; MESSENGER RNA;

ARTICLE; BHLF1 GENE; BURKITT LYMPHOMA; CONTROLLED STUDY; CP GENE; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE LOCUS; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LATENT PERIOD; LYMPHOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SUPERINFECTION; VIRUS GENOME; WP GENE;

B-LYMPHOCYTES; CELL LINE; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; VIRAL PROTEINS; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 80055108873     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05158-11     Document Type: Article

References (83)

1. Abbot, S. D., et al. 1990. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64:2126-2134.
2. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181:595-608.
3. Allday, M. J., D. H. Crawford, and J. A. Thomas. 1993. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells. J. Gen. Virol. 74:361-369.
4. Babcock, G. J., D. Hochberg, and A. D. Thorley-Lawson. 2000. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506.
5. Bell, A., J. Skinner, H. Kirby, and A. Rickinson. 1998. Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter. Virology 252:149-161.
6. Bodescot, M., M. Perricaudet, and P. J. Farrell. 1987. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J. Virol. 61: 3424-3430.
7. Chau, C. M., X. Y. Zhang, S. B. McMahon, and P. M. Lieberman. 2006. Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF. J. Virol. 80:5723-5732.
8. Davenport, M. G., and J. S. Pagano. 1999. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J. Virol. 73:3154-3161.
9. Dolan, A., C. Addison, D. Gatherer, A. J. Davison, and D. J. McGeoch. 2006. The genome of Epstein-Barr virus type 2 strain AG876. Virology 350:164-170.
10. Evans, T. J., M. G. Jacquemin, and P. J. Farrell. 1995. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 206:866-877.
11. Finke, J., et al. 1987. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J. Virol. 61:3870-3878.
12. Gardella, T., P. Medveczky, T. Sairenji, and C. Mulder. 1984. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J. Virol. 50:248-254.
13. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
14. Hochberg, D., et al. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:239-244.
15. Hurley, E. A., et al. 1991. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J. Virol. 65:1245-1254.
16. Hutchings, I. A., et al. 2006. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J. Virol. 80:10700-10711.
17. Jansson, A., M. Masucci, and L. Rymo. 1992. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J. Virol. 66:62-69.
18. Jeang, K. T., and S. D. Hayward. 1983. Organization of the Epstein-Barr virus DNA molecule. III. Location of the P3HR-1 deletion junction and characterization of the NotI repeat units that form part of the template for an abundant 12-O-tetradecanoylphorbol-13-acetate-induced mRNA transcript. J. Virol. 48:135-148.
19. Jin, X. W., and S. H. Speck. 1992. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J. Virol. 66:2846-2852.
20. Kanda, T., M. Yajima, N. Ahsan, M. Tanaka, and K. Takada. 2004. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J. Virol. 78:7004-7015.
21. Kang, M. S., et al. 2005. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc. Natl. Acad. Sci. U. S. A. 102:820-825.
22. Kang, M. S., V. Soni, R. Bronson, and E. Kieff. 2008. Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice. J. Virol. 82:4180-4183.
23. Kelly, G., A. Bell, and A. Rickinson. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098-1104.
24. Kelly, G. L., et al. 2009. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 5(3):e1000341.
25. Kelly, G. L., et al. 2005. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79:10709-10717.
26. Kieff, E. D., and A. B. Rickinson. 2006. Epstein-Barr virus and its replication, p. 2603-2654. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Strauss (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
27. Kirby, H., A. Rickinson, and A. Bell. 2000. The activity of the Epstein-Barr virus BamHI W promoter in B cells is dependent on the binding of CREB/ ATF factors. J. Gen. Virol. 81:1057-1066.
28. Komano, J., M. Sugiura, and K. Takada. 1998. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J. Virol. 72:9150-9156.
29. Laux, G., U. K. Freese, and G. W. Bornkamm. 1985. Structure and evolution of two related transcription units of Epstein-Barr virus carrying small tandem repeats. J. Virol. 56:987-995.
30. Lear, A. L., et al. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J. Virol. 66:7461-7468.
31. Leonard, S., et al. 13 July 2011. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal centre B cells and their relevance to the pathogenesis of Hodgkin's lymphoma. J. Virol. doi:10.1128/JVI.00468-11.
32. Leung, C. S., T. A. Haigh, L. K. Mackay, A. B. Rickinson, and G. S. Taylor. 2010. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc. Natl. Acad. Sci. U. S. A. 107:2165-2170.
33. Levitskaya, J., et al. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
34. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U. S. A. 94:12616-12621.
35. Lieberman, P. M., J. M. Hardwick, and S. D. Hayward. 1989. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J. Virol. 63:3040-3050.
36. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55:710-720.
37. Masucci, M. G., et al. 1989. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J. Virol. 63:3135-3141.
38. Nonkwelo, C., J. Skinner, A. Bell, A. Rickinson, and J. Sample. 1996. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70:623-627.
39. Nuebling, C. M., and N. Mueller-Lantzsch. 1989. Identification and characterization of an Epstein-Barr virus early antigen that is encoded by the NotI repeats. J. Virol. 63:4609-4615.
40. Paulson, E. J., and S. H. Speck. 1999. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J. Virol. 73:9959-9968.
41. Pearson, G. R., et al. 1987. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160:151-161.
42. Puglielli, M. T., N. Desai, and S. H. Speck. 1997. Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J. Virol. 71:120-128.
43. Puglielli, M. T., M. Woisetschlaeger, and S. H. Speck. 1996. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J. Virol. 70:5758-5768.
44. Radkov, S. A., et al. 1997. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J. Virol. 71:8552-8562.
45. Robertson, K. D., and R. F. Ambinder. 1997. Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J. Virol. 71:6445-6454.
46. Robertson, K. D., and R. F. Ambinder. 1997. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 90:4480-4484.
47. Robertson, K. D., S. D. Hayward, P. D. Ling, D. Samid, and R. F. Ambinder. 1995. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol. 15:6150-6159.
48. Rogers, R. P., M. Woisetschlaeger, and S. H. Speck. 1990. Alternative splicing dictates translational start in Epstein-Barr virus transcripts. EMBO J. 9:2273-2277.
49. Rooney, C. M., et al. 1992. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J. Virol. 66:496-504.
50. Ruf, I. K., et al. 1999. Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19:1651-1660.
51. Ruf, I. nK., and J. Sample. 1999. Repression of Epstein-Barr virus EBNA-1 gene transcriptio by pRb during restricted latency. J. Virol. 73:7943-7951.
52. Salamon, D., et al. 2009. Binding of CCCTC-binding factor in vivo to the region located between Rep* and the C promoter of Epstein-Barr virus is unaffected by CpG methylation and does not correlate with Cp activity. J. Gen. Virol. 90:1183-1189.
53. Sample, J., E. B. Henson, and C. Sample. 1992. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66:4654-4661.
54. Sample, J., M. Hummel, D. Braun, M. Birkenbach, and E. Kieff. 1986. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc. Natl. Acad. Sci. U. S. A. 83:5096-5100.
55. Sample, J., and E. Kieff. 1990. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J. Virol. 64:1667-1674.
56. Sandberg, M. L., A. Kaykas, and B. Sugden. 2000. Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression. J. Virol. 74:9755-9761.
57. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines. J. Virol. 69:5039-5047.
58. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1997. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol. Cell. Biol. 17:364-377.
59. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 92:10565-10569.
60. Schlager, S., S. H. Speck, and M. Woisetschlager. 1996. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells. J. Virol. 70:3561-3570.
61. Speck, S. H., A. Pfitzner, and J. L. Strominger. 1986. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc. Natl. Acad. Sci. U. S. A. 83:9298-9302.
62. Sternas, L., T. Middleton, and B. Sugden. 1990. The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells. J. Virol. 64:2407-2410.
63. Sung, N. S., S. Kenney, D. Gutsch, and J. S. Pagano. 1991. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J. Virol. 65:2164-2169.
64. Sung, N. S., J. Wilson, M. Davenport, N. D. Sista, and J. S. Pagano. 1994. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol. Cell. Biol. 14:7144-7152.
65. Tellam, J., et al. 2007. Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes. Eur. J. Immunol. 37:328-337.
66. Tempera, I., A. Wiedmer, J. Dheekollu, and P. M. Lieberman. 2010. CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog. 6(8):e1001048.
67. Thorley-Lawson, D. A. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82.
68. Tierney, R., H. Kirby, J. Nagra, A. Rickinson, and A. Bell. 2000. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J. Virol. 74: 10458-10467.
69. Tierney, R., et al. 2007. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81:10092-10100.
70. Tierney, R. J., et al. 2000. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J. Virol. 74: 10468-10479.
71. Trivedi, P., et al. 2001. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J. Virol. 75:4929-4935.
72. Tsang, S. F., F. Wang, K. M. Izumi, and E. Kieff. 1991. Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J. Virol. 65:6765-6771.
73. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
74. Wang, F., S. F. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64:3407-3416.
75. Woisetschlaeger, M., et al. 1991. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc. Natl. Acad. Sci. U. S. A. 88:3942-3946.
76. Woisetschlaeger, M., C. N. Yandava, L. A. Furmanski, J. L. Strominger, and S. H. Speck. 1990. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 87:1725-1729.
77. Xue, S. A., and B. E. Griffin. 2007. Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication. Nucleic Acids Res. 35:3391-3406.
78. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371-1374.
79. Yoo, L., and S. H. Speck. 2000. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines. J. Virol. 74:11115-11120.
80. Yoo, L. I., M. Mooney, M. T. Puglielli, and S. H. Speck. 1997. B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1. J. Virol. 71:9134-9142.
81. Yoshioka, M., M. M. Crum, and J. T. Sample. 2008. Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J. Virol. 82:1679-1687.
82. Young, L., et al. 1989. Expression of Epstein-Barr virus transformationassociated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085.
83. Zhao, B., and C. E. Sample. 2000. Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/spi-B binding site. J. Virol. 74:5151-5160.